Publications by authors named "L Schachter"
Background: Chimeric antigen receptor T-cell (CAR-T) therapies are available for patients with Non-Hodgkin Lymphoma (NHL); however, their use has been limited in accessibility due to nondisease factors.
Patients & Methods: We conducted a retrospective study evaluating the influence of sociodemographic factors on access and outcomes after CAR-T therapy for adult patients with B-cell NHL in our institution treated between 2016 and 2023.
Results: Among 154 patients treated with CAR-T, 43% were older than 65 years, 68% male, and 14% non-White (including Hispanic).
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19-directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We investigated CART outcomes for R/R THRLBCL through the Center for International Blood and Marrow Transplant Research registry.
View Article and Find Full Text PDFArticle Synopsis
- The study explores access to CART19 immunotherapy for large B-cell lymphomas among minority health populations (MHPs) compared to non-MHPs in different hospital settings.
- It found that while MHPs had access to care for LBCL, their representation in CART19 therapy was lower, with only 6.7% at the Abramson Cancer Center and 4.2% at the Knight Cancer Institute receiving the treatment.
- Outcomes for MHPs who did receive CART19 were similar to non-MHPs regarding response and survival, but the small sample size necessitates further research to confirm these findings.
Purpose: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established.
Methods: We performed an international multicenter retrospective study of patients with RT who received CAR-T.
Background: Peripheral T-cell lymphomas (PTCL) are a group of aggressive malignancies with inferior outcomes compared to B-cell non-Hodgkin lymphoma (NHL). Both allogeneic and autologous hematopoietic cell transplantation (HCT) are commonly employed for consolidation and salvage.
Materials And Methods: We conducted a single-center review of all adult PTCL patients at OHSU who received HCT from 1991 to 2020 with responses assed by CIBMTR criteria.